CG Power Shares Rise Sharply on Plan for Chip JV with Japan, Thai Partners
By Kosaku Narioka
CG Power & Industrial Solutions shares rose sharply on its plan to jointly build and operate a chip plant in India with Japanese and Thai partners.
Shares were recently 5.0% higher at 465.95 Indian rupees on Friday after rising as much as 11% earlier.
CG Power said Thursday after market close that the Indian government had approved the joint-venture project to build and operate a semiconductor assembly and testing facility in Gujarat that will cater to customers in auto, industrial, and 5G industries.
"CG's entry into the semiconductor manufacturing marks a strategic diversification for us," said CG Power Chairman Vellayan Subbiah. "We are very keen to build out India's semiconductor capability and ecosystem."
The Mumbai-based electrical engineering company will own a 92.3% stake in the joint venture, while Japan's Renesas Electronics will hold a 6.8% stake and Thailand's Stars Microelectronics will have a 0.9% interest. The joint venture plans to invest INR76.00 billion ($916.7 million) over five years, CG Power said.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
March 01, 2024 01:47 ET (06:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks